National Research Corp
$
50.2
0 (0%)
On watch
| Volume: | 19,386 | Avg Vol (1m): | 32,350 |
| Market Cap $: | 1.25 Bil | Enterprise Value $: | 1.28 Bil |
| P/E (TTM): | 0.00 | P/B: | 57.06 |
| Earnings Power Value | 8.94 |
| Net Current Asset Value | -2.28 |
| Tangible Book | -1.44 |
| Projected FCF | 9.5 |
| Median P/S Value | 3.26 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 6/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 0.07 |
Cash-To-Debt ranked
higher than
65.13%
of
261
companies
in the
Diagnostics & Research
industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
NRC:
0.07
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.05, Med: 2.01, Max: 10000
Current: 0.07
|
| Equity-to-Asset | 0.22 |
Equity-to-Asset ranked
higher than
66.11%
of
239
companies
in the
Diagnostics & Research
industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
NRC:
0.22
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.18, Med: 0.67, Max: 0.81
Current: 0.22
|
| Debt-to-Equity | 1.70 |
Debt-to-Equity ranked
higher than
93.29%
of
164
companies
in the
Diagnostics & Research
industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
NRC:
1.7
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.16, Max: 1.99
Current: 1.7
|
| Debt-to-EBITDA | 0.89 |
Debt-to-EBITDA ranked
higher than
99.14%
of
116
companies
in the
Diagnostics & Research
industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
NRC:
0.89
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: 0.03, Med: 0.4, Max: 0.91
Current: 0.89
|
| Interest Coverage | 17.83 |
Interest Coverage ranked
higher than
57.67%
of
163
companies
in the
Diagnostics & Research
industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
NRC:
17.83
Ranked among companies with meaningful Interest Coverage only.
|
Interest Coverage range over the past 10 years
Min: 23.31, Med: 52.24, Max: 417.3
Current: 17.83
|
| Piotroski F-Score | 6 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 7.42 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -3.36 |
Not Manipulator
Manipulator
| |
Profitability & Growth : 5/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 30.81 |
Operating Margin ranked
higher than
95.04%
of
242
companies
in the
Diagnostics & Research
industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
NRC:
30.81
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: 21.86, Med: 26.54, Max: 29.47
Current: 30.81
|
| Net Margin % | 25.75 |
Net Margin ranked
higher than
92.53%
of
241
companies
in the
Diagnostics & Research
industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
NRC:
25.75
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: 13.41, Med: 17.33, Max: 25.1
Current: 25.75
|
| ROE % | 79.42 |
ROE ranked
higher than
93.80%
of
242
companies
in the
Diagnostics & Research
industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
NRC:
79.42
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: 18.33, Med: 23.44, Max: 54.89
Current: 79.42
|
| ROA % | 27.86 |
ROA ranked
higher than
94.27%
of
262
companies
in the
Diagnostics & Research
industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
NRC:
27.86
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: 10.1, Med: 14.84, Max: 25.53
Current: 27.86
|
| ROC (Joel Greenblatt) % | 276.37 |
ROC (Joel Greenblatt) ranked
higher than
98.46%
of
259
companies
in the
Diagnostics & Research
industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
NRC:
276.37
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: 97.03, Med: 220.15, Max: 284.42
Current: 276.37
|
| 3-Year Total Revenue Growth Rate | 5.40 |
3-Year Revenue Growth Rate ranked
higher than
52.20%
of
182
companies
in the
Diagnostics & Research
industry.
Industry Max: 371, Med: 4.8, Min: -100
NRC:
-30.5
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
| N/A |
| 3-Year Total EBITDA Growth Rate | 9.60 |
3-Year EBITDA Growth Rate ranked
lower than
53.37%
of
178
companies
in the
Diagnostics & Research
industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
NRC:
-27.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
| N/A |
| 3-Year EPS w/o NRI Growth Rate | -100.00 |
3-Year EPS w/o NRI Growth Rate ranked
lower than
50.31%
of
163
companies
in the
Diagnostics & Research
industry.
Industry Max: 138.7, Med: 10.1, Min: -301
NRC:
-100
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
| N/A |
» NRC's 30-Y Financials
Financials (Next Earnings Date: 2019-08-01 Est.)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:NRC
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Medical Diagnostics & Research » Diagnostics & Research   NAICS : 621399   SIC : 8099 |
| Compare | NAS:FLDM NAS:LNTH HKSE:01763 OSTO:CEVI SHSE:600055 SZSE:300439 TSE:4282 SZSE:300685 NAS:TWST SHSE:603108 LSE:IDHC XBRU:BCART SZSE:300396 NAS:AXDX NAS:PACB SHSE:603127 BSP:PARD3 NAS:CDNA SHSE:603716 NAS:RDNT |
| Traded in other countries | NR1A.Germany |
| Address | 1245 Q Street, Lincoln, NE, USA, 68508 |
| National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. The company's portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The company operates in US and Canada. The maximum revenue derives from the United States. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Owner-Earnings | 38.61 |
Price-to-Owner-Earnings ranked
higher than
85.53%
of
76
companies
in the
Diagnostics & Research
industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
NRC:
38.61
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 1.42, Med: 3.69, Max: 55.74
Current: 38.61
|
| PB Ratio | 57.06 |
PB Ratio ranked
lower than
89.80%
of
245
companies
in the
Diagnostics & Research
industry.
Industry Max: 270, Med: 4.02, Min: 0.15
NRC:
57.06
Ranked among companies with meaningful PB Ratio only.
| N/A |
| PS Ratio | 10.80 |
PS Ratio ranked
higher than
59.13%
of
230
companies
in the
Diagnostics & Research
industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
NRC:
10.8
Ranked among companies with meaningful PS Ratio only.
| N/A |
| Price-to-Free-Cash-Flow | 39.18 |
Price-to-Free-Cash-Flow ranked
higher than
85.00%
of
80
companies
in the
Diagnostics & Research
industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
NRC:
39.18
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
| N/A |
| Price-to-Operating-Cash-Flow | 33.34 |
Price-to-Operating-Cash-Flow ranked
higher than
81.44%
of
97
companies
in the
Diagnostics & Research
industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
NRC:
33.34
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
| N/A |
| EV-to-EBIT | 25.00 |
EV-to-EBIT ranked
higher than
56.78%
of
118
companies
in the
Diagnostics & Research
industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
NRC:
25
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: 1.5, Med: 3.3, Max: 37.9
Current: 25
|
| EV-to-EBITDA | 21.77 |
EV-to-EBITDA ranked
higher than
50.76%
of
132
companies
in the
Diagnostics & Research
industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
NRC:
21.77
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: 1.2, Med: 2.7, Max: 33.1
Current: 21.77
|
| EV-to-Revenue | 7.84 |
EV-to-Revenue ranked
lower than
62.81%
of
242
companies
in the
Diagnostics & Research
industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
NRC:
7.84
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 0.4, Med: 0.8, Max: 10.7
Current: 7.84
|
| Shiller PE Ratio | 17.15 |
Shiller PE Ratio ranked
higher than
94.87%
of
39
companies
in the
Diagnostics & Research
industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
NRC:
17.15
Ranked among companies with meaningful Shiller PE Ratio only.
|
Shiller PE Ratio range over the past 10 years
Min: 3.47, Med: 6.99, Max: 18.57
Current: 17.15
|
| Current Ratio | 0.58 |
Current Ratio ranked
lower than
70.00%
of
250
companies
in the
Diagnostics & Research
industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
NRC:
0.58
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 0.49, Med: 1.53, Max: 5.41
Current: 0.58
|
| Quick Ratio | 0.58 |
Quick Ratio ranked
lower than
64.00%
of
250
companies
in the
Diagnostics & Research
industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
NRC:
0.58
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.49, Med: 1.53, Max: 5.41
Current: 0.58
|
| Days Sales Outstanding | 48.27 |
Days Sales Outstanding ranked
higher than
77.94%
of
204
companies
in the
Diagnostics & Research
industry.
Industry Max: 521.64, Med: 67.51, Min: 1
NRC:
48.27
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 29.97, Med: 39.95, Max: 53.89
Current: 48.27
|
| Days Payable | 12.06 |
Days Payable ranked
lower than
96.79%
of
187
companies
in the
Diagnostics & Research
industry.
Industry Max: 981.81, Med: 63.34, Min: 1
NRC:
12.06
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 3, Med: 6.14, Max: 14.16
Current: 12.06
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| Dividend Yield % | 1.43 |
Trailing Dividend Yield ranked
higher than
95.87%
of
121
companies
in the
Diagnostics & Research
industry.
Industry Max: 10.16, Med: 0.81, Min: 0.07
NRC:
1.43
Ranked among companies with meaningful Trailing Dividend Yield only.
|
Trailing Dividend Yield range over the past 10 years
Min: 0.94, Med: 12.86, Max: 23.19
Current: 1.43
|
| Dividend Payout Ratio | 2.06 |
Dividend Payout Ratio ranked
higher than
98.57%
of
70
companies
in the
Diagnostics & Research
industry.
Industry Max: 6.35, Med: 0.32, Min: 0.03
NRC:
2.06
Ranked among companies with meaningful Dividend Payout Ratio only.
| N/A |
| 3-Year Dividend Growth Rate (Per Share) | -100.00 |
3-Year Dividend Growth Rate ranked
higher than
86.11%
of
36
companies
in the
Diagnostics & Research
industry.
Industry Max: 77.2, Med: 9.9, Min: -100
NRC:
-100
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
| N/A |
| Forward Dividend Yield % | 1.58 |
Forward Dividend Yield ranked
higher than
92.04%
of
113
companies
in the
Diagnostics & Research
industry.
Industry Max: 10.53, Med: 1.1, Min: 0.07
NRC:
1.58
Ranked among companies with meaningful Forward Dividend Yield only.
| N/A |
| Yield-on-Cost (5-Year) % | 1.43 |
Yield-on-Cost (5y) ranked
higher than
87.32%
of
142
companies
in the
Diagnostics & Research
industry.
Industry Max: 12, Med: 1.41, Min: 0.08
NRC:
1.43
Ranked among companies with meaningful Yield-on-Cost (5y) only.
|
Yield-on-Cost (5y) range over the past 10 years
Min: 0.94, Med: 12.86, Max: 23.19
Current: 1.43
|
| 3-Year Share Buyback Rate | -0.20 |
3-Year Share Buyback Rate ranked
higher than
83.89%
of
180
companies
in the
Diagnostics & Research
industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
NRC:
-0.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -93.8, Med: -0.1, Max: 0
Current: -0.2
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Earnings Yield (Joel Greenblatt) % | 4.00 |
Earnings Yield (Greenblatt) ranked
higher than
80.75%
of
265
companies
in the
Diagnostics & Research
industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
NRC:
4
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2.6, Med: 30.1, Max: 68.2
Current: 4
|
| Forward Rate of Return (Yacktman) % | -5.00 |
Forward Rate of Return ranked
lower than
75.71%
of
70
companies
in the
Diagnostics & Research
industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
NRC:
-5
Ranked among companies with meaningful Forward Rate of Return only.
|
Forward Rate of Return range over the past 10 years
Min: -3.1, Med: 36.45, Max: 66.3
Current: -5
|
More Statistics
| Revenue (TTM) (Mil) $ | 120.15 |
| EPS (TTM) $ | 2.68 |
| Beta | 0.69 |
| Volatility % | 12.68 |
| 52-Week Range $ | 32.98 - 51.29 |
| Shares Outstanding (Mil) | 24.86 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 6 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | N |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | Y |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | N |